Mechanism of actions of antidepressants: Beyond the receptors

Klinik Psikofarmakoloji Bulteni

Volumn 12, Issue 4, 2002, Pages 194-200

  Yildiz, Aysȩgül ^a,d   Gönül, Ali Saffet ^b   Tamam, Lut ^c  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c CUKUROVA UNIVERSITY   (Turkey)

^d NONE   (Turkey)

Author keywords

Adaptation; Antidepressants; Mechanism of action; Neuroplasticity

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOPAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; REBOXETINE; SEROTONIN; SERTRALINE; TIANEPTINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE EXPRESSION; NERVE CELL PLASTICITY; REVIEW; SYNAPTIC TRANSMISSION;

EID: 0036984129     PISSN: 10177833     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Stahl SM. Basic psychopharmacology of antidepresssants, Part I: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998;59(suppl 4):5-14.
2. Sambunaris A, Hesselink JK, Pinder R, Panagides J, Stahl SM. Development of new antidepressants. J Clin Psychiatry 1997;58(suppl 6):40-53.
3. Richelson E. Pharmacology of antidepressants in use in the United States. J Clin Psychiatry 1982;43:4-13.
4. DE Montigny C, Pineyro G, Chaput Y, Blier P. Electrophysiological studies on the effect of long-term 5-HT reuptake inhibition on the function of 5HT neurons. Clin Neuropharmacol 1992;115 (suppl 1 A):440A-441A.
5. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depresssion. J Clin Psychopharmacol 1987;7(6 Suppl):24S-35S.
6. Blier P, de Montigny C. Current advances and trends in the reatment of depression. Trends Pharmacol Sci 1994;15:220-226.
7. Baxter LR Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989;46:243-250.
8. Foote SL, Morrison JH. Development of noradrenergic, serotonergic, and dopaminergic innervation of neocortex. Curr Top Dev Biol 1987;21:391-423.
9. Balon R. The effects of antidepressants on human sexuality: Diagnosis and management update 1996. Primary Psychiatry 1997;4:32-48.
10. Stein DJ, Hollander E. Sexual dysfunction associated with the drug treatment of psychiatric disorders. CNS Drugs 1994;2:78-86.
11. Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double blind comparison with orphenadrine and placebo. Clin Neropharmacol 1990;13:500-506.
12. Gorman J, Liebowicz MR, Fyer AJ. A neurochemical hypothesis for panic disorder. Am J Psychiatry 1989;150:1480-1484.
13. Costall B, Naylor RJ, Tyers MB. The psychopharmacology of 5-HT3 receptors. Pharmacol Ther 1990;47:181-202.
14. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-1029.
15. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 1994; 11:133-141.
16. Breese GR, Cooper BR, Hollister AS. Relationship of biogenic amines to behavior. J Psychiatr Res 1974;11:125-133.
17. Casat CD, Pleasants DZ, Schroeder DH, Parler DW. Bupropion in children with attention deficit disorder. Psychopharmacol Bull 1989;25:198-201.
18. Goldstein MG. Bupropion sustained release and smoking cessation. J Clin Psychiatry 1998;59 (suppl 4):66-72.
19. Settle EC Jr. Bupropion sustained release: side effect profile. J Clin Psychiatry 1998;59 (suppl 4):32-36.
20. Davidson JRT, Conner KM. Bupropion sustained release. J Clin Psychiatry 1998;59 (suppl 4):25-31.
21. Stahl SM. Remeron (mirtazapine): a novel antidepresssant that disinhibits serotonin and norepinephrine by alpha-2 antagonism. Psychiatric Annals 1997;27:14-16.
22. DeBattista C, Schatzberg AF. Other biological and pharmacological therapies. In: Comprehensive Textbook of Psychiatry (Eds Sadock BJ, Sadock VA), 7th edition, Lippincott Williams & Wilkins, Philadelphia, 2000:2521-2531.
23. Wilde MI, Benfield P, Defrance R, Marey C, Kamoun A. Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials. Clin Neuropharmacol 1988;11(Suppl 2):74-82.
24. Loo H, Deniker P. Position of tianeptine among antidepressive chemotherapies. Clin Neuropharmacol 1988;11(Suppl2):S97-102.
25. Hyman SE. The neurobiologic basis of emotion, frontiers of neuropsychopharmacol. National Institute of Mental Health: August 1998.
26. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153:151-162.
27. Rogan MT, LeDoux JE: Emotion: systems, cells, synaptic plasticity. Cell 1996;85(4):469-475.
28. Bourin M, Baker GB. The future of antidepressants. Biomed Pharmacother 1996;50:7-12.
29. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000;5:578-593.
30. Gould, T.D., Manji, HK. Signaling networks in the pathophysiology and treatment of mood disorders. J Psychosom Res 2002;53:687-697.
31. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606.
32. Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000;48:732-739.
33. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000;48:740-754.
34. Gould E, Vail N, Wagers M, Gross CG. Adult-generated hippocampal and neocortical neurons in macaques have a transient existence. Proc Natl Acad Sci U S A 2001;98:10910-10917.
35. Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol Psychiatry 2000;48:791-800.
36. Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res. 2000;126:413-431.
37. Rajkowska G. Histopathology of the prefrontal cortex in major depression: what does it tell us about dysfunctional monoaminergic circuits? Prog Brain Res 2000;126:397-412.
38. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 2000;886:172-189.
39. Shirayama Y, Chen ACH, Duman RS. Antidepressant-like effects of BDNF and NT-3 in beharioral models of depression. Abstr Soc Neurosci 2000;26:102-106.
40. Sulser F, Vetulani J, Mobley PL. Mode of action of antidepressant drugs. Biochem Pharmacol 1978;27:257-261.
41. Schultz JE, Siggins GR, Schocker FW, Turck M, Bloom FE. Effects of prolonged treatment with lithium and tricyclic antidepressants on discharge frequency, norepinephrine response, and beta receptor binding in rat cerebellum: electrophysiological and biochemical comparison. J Pharmacol Exp Ther 1981;216:28-38.
42. Rosin DL, Melia K, Knorr AM, Nestler EJ, Roth RH, Duman RS. Chronic imipramine administration alters the activity and phosphorylation state of tyrosine hydroxylase in dopaminergic regions of rat brain. Neuropsychopharmacology 1995; 12:113-121.
43. Yildiz A, Sachs GS. Administration of antidepressants single versus split dosing: a meta-analysis. J Affect Dis 2001;66:199-206.
44. Yildiz A, Sachs GS. Administration of antidepressants; single versus split dosing: A meta-analysis. Evidence Based Mental Health 2002;5:57.